BioWorld

Dec. 19, 2002

Eyetech Signs Potential $750M Deal With Pfizer For Macugen

Eyetech Pharmaceuticals Inc. could gain about $750 million in a deal with Pfizer Inc. centered on development and commercialization of Macugen, Eyetech's lead drug candidate for age-related macular degeneration and diabetic macular edema. (BioWorld Today) Read More

Lexicon, Genentech Form $39M Drug Discovery Deal

15-Year Clinical Trial Of 180 Brain Tumor Patients Shows Life Survival Potential Of Antibody, Radiation

Angiogenix Raises $12M In Series C For Acclaim Product

Other News To Note

Today's news in brief

BioWorld

3D rendering of skin cells and elastin with collagen layer

First-in-class pan-inflammasome blocker for hidradenitis suppurativa

BioWorld Science

Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld

Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...

Illustration of cancer cell in crosshairs being destroyed

RX-10616 improves radiotherapy efficacy in HNSCC

BioWorld Science

Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...

CROI 2026: Neurodegeneration, the challenge of aging with HIV

BioWorld

Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...